# A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

> **NCT00817635** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 155 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** LCI699
- **DRUG:** Eplerenone
- **DRUG:** LCI699-matching Placebo
- **DRUG:** Eplerenone-matching Placebo

## Key facts

- **NCT ID:** NCT00817635
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-22
- **Primary completion:** 2009-10-13
- **Final completion:** 2009-10-13
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2021-06-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00817635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00817635, "A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00817635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*